Key result
Systemic inflammation linked to ~28% higher MACE risk in HFpEF and HFmrEF.
Why the study?
Does systemic inflammation (hsCRP 2-10 mg/L) increase the risk of major adverse cardiovascular events, acute care utilization, and healthcare costs compared to no systemic inflammation (hsCRP <2 mg/L) in Veterans with HFpEF or HFmrEF?
Cohort (n=49,986)
Does systemic inflammation (hsCRP 2-10 mg/L) increase the risk of major adverse cardiovascular events, acute care utilization, and healthcare costs compared to no systemic inflammation (hsCRP <2 mg/L) in Veterans with HFpEF or HFmrEF?
Hazard Ratio: 1.28 (95% CI 1.24–1.33)
Absolute Event Rate: 15.1% vs 11.8%
p-value: p=<0.001
In Veterans with HFpEF or HFmrEF, systemic inflammation (hsCRP 2-10 mg/L) is independently associated with a 28% higher risk of MACE, increased all-cause hospitalizations, and $9,112 in additional annual healthcare costs per patient.
SI associated with higher death and HF events in veterans with HFpEF/HFmrEF; leaves open whether inflammation-targeted therapies improve outcomes.
BACKGROUND: The association between systemic inflammation (SI) and outcomes among patients with heart failure with preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF) is uncertain. OBJECTIVES: This study aimed to evaluate the association between SI and clinical and economic outcomes among individuals with HFpEF/HFmrEF. METHODS: We identified Veterans with HFpEF/HFmrEF with outpatient high-sensitivity C-reactive protein (hsCRP) testing from 2008 to 2022. We classified Veterans as with SI (hsCRP 2-10 mg/L) and without SI (hsCRP <2 mg/L). The primary outcome was the 3-component major adverse cardiovascular event (MACE) outcome of death, HF hospitalization, and HF-related emergency department encounters. Additional outcomes included acute care utilization and costs. We evaluated the adjusted associations between SI and clinical outcomes, acute care utilization, and costs via Cox regression, negative binomial regression, and gamma regression, respectively. RESULTS: We identified 49,986 Veterans with HFpEF/HFmrEF with outpatient hsCRP levels. We compared 8,696 (17.4%) Veterans without SI (hsCRP <2 mg/L) and 25,352 (50.7%) Veterans with SI (hsCRP ≥2 mg/L and ≤10 mg/L Over a median follow-up of 3.4 years (IQR: 1.8-5.8), MACE incidence was 15.1/100 patient-years (95% CI: 14.9-15.4) among those with SI vs 11.8/100 patient-years (95% CI: 11.4-12.1) among those without SI (P < 0.001). After adjustment, SI was associated with increased MACE (HR: 1.28; 95% CI: 1.24-1.33). SI was also associated with increased all-cause hospitalizations (incidence rate ratio: 1.19; 95% CI: 1.137-1.246) and $9,112 (95% CI: $6,135-$12,089) in additional per-patient costs over 1 year. CONCLUSIONS: Among Veterans with HFmrEF/HFpEF, SI is associated with increased adverse clinical outcomes and higher costs.
No takes yet. Share an insight, caveat, or question.
Sandhu et al. (2026) conducted a cohort in Heart failure with preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF) (n=49,986). Systemic inflammation (hsCRP 2-10 mg/L) vs. No systemic inflammation (hsCRP <2 mg/L) was evaluated on 3-component major adverse cardiovascular event (MACE) of death, HF hospitalization, and HF-related emergency department encounters (HR 1.28, 95% CI 1.24-1.33, p=<0.001). Systemic inflammation (hsCRP 2-10 mg/L) in Veterans with HFpEF/HFmrEF was associated with increased MACE compared with hsCRP <2 mg/L (HR 1.28; 95% CI 1.24-1.33; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: